Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 56 for “"CTLA-4"”.
-
Ctla-4 transcriptional activation: regulation of induced expression
<p>Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a T cell surface protein that is homologous to CD28 and binds to the B7 family of ligands. Unlike CD28, CTLA-4 interaction transmits a negative signal in T cells, leading to suppression of proliferation. CTLA-4 is constitutively expressed on …
-
Mechanistic Elucidation and Therapeutic Improvement of Anti-CTLA-4 Therapies
Anti-CTLA-4 antibodies have successfully elicited durable tumor regression in the clinic; however, long-term benefit is limited to a subset of patients for select cancer indications. The incomplete understanding of their mechanism of action has hindered efforts at improvement, with conflicting …
-
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells
… rats were examined. At the molecular level, rat CTLA-4, a receptor important for deactivating T cell responses, was examined for the expression pattern and in vitro functions. For this purpose, anti-rat CTLA-4 mAbs were generated. Consistent with the studies in mice and humans, rat CTLA-4 was …
-
Role of the CTLA-4 receptor in regulatory T cell development, homeostasis and function
… that the cytotoxic T lymphocyte antigen-4 (CTLA-4) receptor is constitutively expressed by regulatory T cells and a role for this molecule in Treg suppression has been suggested. This investigation revealed a role for CTLA-4 in maintaining homeostasis of the peripheral regulatory T cell …
-
Integrative Cancer Immunogenomic Analysis of Serial Melanoma Biopsies Reveals Correlates of Response and Resistance to Sequential Ctla-4 and Pd-1 Blockade Treatment
… against cytotoxic T lymphocyte antigen–4 (CTLA-4) followed by programmed death receptor–1 (PD-1) by immunogenomic profile analyses from serial tumor biopsies.</p> <p>From immune profiling (12 marker immunohistochemistry and NanoString Gene Expression Profiling), we found that adaptive …
-
Ανοσοθεραπεία κατόπιν της εμφάνισης προόδου νόσου σε διπλή ανοσοθεραπεία: Πεμπρολιζουμάμπη και Λενβατινίμπη έναντι συμβατικής χημειοθεραπείας σε ασθενείς με μεταστατικό μελάνωμα κατόπιν αποτυχίας αναστολής των PD-1/CTLA-4 σημείων ελέγχου του ανοσοποιητικού / Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
… (Cytotoxic T-Lymphocyte-Associated Protein-4, CTLA-4), ή η εξαρχής συγχορήγηση των δύο ως συνδυαστική αναστολή, έχει επιφέρει δραστική βελτίωση όσων αφορά την επιβίωση των ασθενών με μεταστατικό μελάνωμα. Ωστόσο, σημαντικό ποσοστό εξ ’αυτών αναπτύσσει πρωτογενή ή επίκτητη ανθεκτικότητα και …
-
Defining The Cooperation Between Mhc-I and Mhc-Ii Neoantigen-Driven T Cell Responses to Develop Effective Personalized Immunotherapies
<p>Immune checkpoint therapy (ICT) (e.g. anti-CTLA-4 (α-CTLA-4), anti-PD-1 (α-PD-1)) enables durable T cell-dependent anti-tumor immunity in certain cancer patients. Since a subset of patients respond to ICT, this work aims at developing a more in-depth understanding of T-cell responses to MHC …
-
Role of the Gut Microbiome in Cancer Immunotherapy Efficacy and Side Effects
… on cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed cell death protein 1 (PD-1) blockade. The research examined how gut microbiota dysbiosis influences T cell populations in various intestinal compartments during CTLA-4 blockade therapy, the connection between specific …
-
Altered Expression of Costimulatory Molecules in Behcet's Disease According to Clinical Activity
… includes the cytotoxic T-lymphocyte antigen-4 (CTLA-4)/CD80, CD86 and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) receptor/ligand systems are important. Also, regulatory T (Treg) cells play an important role in maintaining immune homeostasis. PURPOSE: The objective of the present …
-
Role Of Il-27 And Tcr Stimulation In Inhibitory Receptor Expression
… stimulation to further upregulate Ly6C, LAG-3, CTLA-4, TIGIT and TIM-3. This IL-27-mediated inhibitory expression was STAT1- dependent. The response to TCR stimulation was graded and thus a stronger TCR stimulus resulted in greater inhibitory receptor expression. In vivo, during infection with …
-
Studies on the differentiation of inflammatory and regulatory T-cells
… and IL-22) whilst enhancing regulatory markers (CTLA-4, CD25, FoxP3 and IL-10). Consistently, 1,25(OH)\(_2\)D\(_3\)-treated T-cells suppressed division of naive T-cells stimulated by dendritic cells (DCs). Strong up-regulation of CTLA-4 by 1,25(OH)\(_2\)D\(_3\)reduced B7 expression by DCs, …
-
Perfil de expressão de genes relacionados a doenças autoimunes/inflamatórias em indivíduos com síndrome de down
… da homeostase do sistema imunológico, como o CTLA-4 e PTPN22. O presente estudo avaliou o perfil de expressão dos genes NLRP1, NLRP3, IL-1β, CTLA-4 e PTPN22 em indivíduos com SD suscetíveis ao desenvolvimento de doenças autoimunes/inflamatórias. Além disso, avaliamos se os pacientes com SD …
-
Smac Mimetic and Combination Immunotherapy for the Treatment of Urothelial Cell Carcinoma
… cytotoxic T lymphocyte-associated protein 4 (CTLA-4, 9h10 clone) potentiated anticancer immunity, curing all tested subjects of MB49. I verified Fc receptor-dependent intratumoural regulatory T cell depletion as a required mechanism for enhancing survival probability with the combination of SM …
-
Bhlhe40: Required For Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
… the use of monoclonal antibodies, such as anti-CTLA-4 or anti-PD-1 that block the receptors from binding with their ligands, thus allowing for CD4<sup>+</sup> and CD8<sup>+</sup> T cell priming and activation(Wei et al., 2017). However, the required epigenetic and transcriptional features that T …
-
Monogenetic Immune Dysregulation Syndromes and their Effect on the Plasma Cell Compartment
… Abatacept is a biological agent, stabilising CTLA-4 signalling, used for many years to treat RA, it is currently under investigation for the treatment of CHAI: a condition caused by CTLA-4 insufficiency leading to unchecked immunomodulation. The frequencies of CCR10+ PC, were significantly …
-
Modulating the gut microbiome to improve immune checkpoint inhibitor response to cancer: current therapies and emerging methods
… 1 (PD-1) and T-lymphocyte-associated protein 4 (CTLA-4) are the two most targeted immune checkpoint proteins. Antibodies against PD-1 and CTLA-4, as well as other checkpoint proteins, are approved for clinical use as well as in clinical trials. While ICIs have changed the treatment landscape for …
-
Tumor Immunotherapy: Mechanisms of Acquired Resistance and Characterization of Immune Related to xicities
… complete resistance to combination blockade of CTLA-4, PD-1, and PD-L1, which cures ~80% of mice bearing the parental tumor. Using gene expression analysis, and immunogenomics, we determined the adaptations engaged by this melanoma to become completely resistant to triple combination T cell …
-
Interrogating the functional adaptions of Tumour-draining lymph nodes (TDLNs) and the subsequent impact of checkpoint inhibition
… suppressive markers, including TGF-B, CTLA-4 and FasL. Concurrently, CD4 and CD8 T cells show diminished secretion of IL-2 and IFNy, common markers of T cell activation. Localisation of Tregs also differed in TDLNs, displaying closer contacts with stromal fibroblastic reticular cells …
-
The Treatment of Solid Tumours with Complete Freund's Adjuvant
… carcinoma. Combination therapy with CFA and anti-CTLA-4, which blocks the inhibitory effects of CTLA-4 on T cells, did not improve CFA treatment efficacy in either the P815 or 4T1 models, but was found to be effective against CT26 cancers. This thesis presents a novel technique for identifying …
-
The Treatment of Solid Tumours with Complete Freund's Adjuvant
… carcinoma. Combination therapy with CFA and anti-CTLA-4, which blocks the inhibitory effects of CTLA-4 on T cells, did not improve CFA treatment efficacy in either the P815 or 4T1 models, but was found to be effective against CT26 cancers. This thesis presents a novel technique for identifying …
Page 1 of 3